BridgeBio Pharma (BBIO) Payables (2018 - 2025)
BridgeBio Pharma's Payables history spans 8 years, with the latest figure at $36.2 million for Q4 2025.
- On a quarterly basis, Payables rose 276.67% to $36.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.2 million, a 276.67% increase, with the full-year FY2025 number at $36.2 million, up 276.67% from a year prior.
- Payables hit $36.2 million in Q4 2025 for BridgeBio Pharma, up from $18.7 million in the prior quarter.
- Over the last five years, Payables for BBIO hit a ceiling of $36.2 million in Q4 2025 and a floor of $3.9 million in Q2 2023.
- Historically, Payables has averaged $13.7 million across 5 years, with a median of $11.1 million in 2022.
- Biggest five-year swings in Payables: crashed 60.62% in 2022 and later soared 482.17% in 2025.
- Tracing BBIO's Payables over 5 years: stood at $11.9 million in 2021, then fell by 2.74% to $11.6 million in 2022, then dropped by 7.81% to $10.7 million in 2023, then fell by 9.73% to $9.6 million in 2024, then skyrocketed by 276.67% to $36.2 million in 2025.
- Business Quant data shows Payables for BBIO at $36.2 million in Q4 2025, $18.7 million in Q3 2025, and $26.1 million in Q2 2025.